SenesTech, Inc. (SNES) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. SenesTech, Inc. develops and commercializes fertility control products for managing animal pest populations, primarily rats and mice. Key products include ContraPest (liquid bait) and the Evolve line (soft bait containing cottonseed oil). The company is headquartered in Surprise, Arizona, and operates as a single segment focused on the formulation, development, and sale of these products.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Net Revenue | $690,000 | $482,000 | $1,800,000 | $1,356,000 |
| Gross Profit | $433,000 | $315,000 | $1,155,000 | $699,000 |
| Gross Margin | 62.8% | 65.4% | 64.2% | 51.5% |
| Net Loss | $(1,298,000) | $(1,513,000) | $(4,579,000) | $(4,929,000) |
| Operating Cash Flow | N/A | N/A | $(4,086,000) | $(4,815,000) |
| Cash & Equivalents | $7,278,000 | $1,307,000 | $7,278,000 | $2,518,000 |
| Short-term Investments | $2,970,000 | $0 | $2,970,000 | $0 |
| Total Liquidity | $10,248,000 | $1,307,000 | $10,248,000 | $2,518,000 |
| Notes Payable (Total) | $220,000 | $262,000 | $220,000 | $262,000 |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 43% year-over-year, driven primarily by the Evolve product line, which now accounts for approximately 85% of total revenue (up from 69% in Q3 2024). Evolve Rat and Evolve Mouse sales grew significantly across e-commerce and professional channels.
- Margin Expansion: Gross margin improved to 64.2% for the nine months ended September 2025, compared to 51.5% in the prior year. This improvement is attributed to a favorable product mix shift toward Evolve and lower input costs as the company transitioned from development-stage pricing to production-scale sourcing.
- Liquidity Position: Total liquidity (cash, cash equivalents, and short-term investments) surged to $10.2 million from $1.3 million at year-end 2024. This increase was fueled by $13.1 million in net financing proceeds, primarily from warrant exercises and an At-The-Market (ATM) offering.
- Cost Management: Operating expenses decreased slightly in Q3 2025 compared to Q3 2024, despite higher facility costs associated with a new manufacturing site. Research and Development (R&D) expenses declined due to headcount adjustments, while Selling, General, and Administrative (SG&A) expenses were offset by higher legal fees related to ongoing litigation.
Guidance, Outlook, and Risks
- Going Concern: Management states that the "substantial doubt" regarding the company's ability to continue as a going concern, previously noted in prior filings, has been alleviated. The company believes its current cash position of $10.2 million is sufficient to fund operations for the next 12 months.
- Outlook: The company expects to continue incurring operating losses in the near term. Future success depends on the commercialization of fertility control products, market acceptance, and the ability to raise additional capital if revenue targets are not met.
- Legal Contingency: The company is defending against a lawsuit filed by Liphatech Inc. alleging breach of contract, misappropriation of trade secrets, and unfair competition. No damages have been accrued as the outcome is not currently probable or estimable.
- Capital Needs: While current funds are deemed sufficient for 12 months, the company may require additional financing to achieve profitability and fund R&D. Failure to secure capital could force delays in commercialization or discontinuation of operations.
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of the Evolve product line, which now represents the vast majority of revenue, and monitor the continued decline in legacy ContraPest sales.
- Litigation Impact: Monitor the status of the Liphatech Inc. lawsuit for any potential financial impact or operational restrictions.
- Dilution Risk: Review the significant number of outstanding warrants (over 3.2 million shares) and the recent warrant inducement transactions, which may lead to future dilution upon exercise.
- Cash Burn Rate: Assess the company's ability to extend its runway beyond the stated 12-month period given the continued net losses and operating cash outflows.
- Regulatory Status: Confirm the expansion of state registrations for Evolve Mouse and any progress on international regulatory approvals.